MedTrace Logo

NRX-1074 in Early Course Schizophrenia

NCT02603458 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-02-05

No results posted yet for this study

Summary

This study seeks to examine the effectiveness of NRX-1074 in the treatment of negative symptoms and cognition in schizophrenia compared to other agents at the glycine site which have demonstrated inconsistent results for negative symptoms. In addition to testing efficacy, we will examine the time course of response of symptoms as well as any effects on memory consolidation.

Conditions

Interventions

DRUG

NRX-1074

Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.

DRUG

Placebo

Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.

Sponsors & Collaborators

  • Naurex, Inc, an affiliate of Allergan plc

    collaborator INDUSTRY

  • NYU Langone Health

    lead OTHER

Principal Investigators

  • Donald C Goff, MD · NYU Langone Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2020-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02603458 on ClinicalTrials.gov